Lu-AG22515 is under clinical development by H. Lundbeck and currently in Phase I for Rheumatoid Arthritis. According to GlobalData, Phase I drugs for Rheumatoid Arthritis have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Lu-AG22515’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Lu-AG22515 is under development for the treatment of neuromyelitis optica spectrum disorder (NMOSD), systemic lupus erythematosus, multiple sclerosis and rheumatoid arthritis. The drug candidate is being developed based on human monoclonal antibody iroduction technology and acts by targeting CD154. It is administered through Intravenous route. It is developed based on AprilBio’s SAFA technology platform.
H. Lundbeck overview
H. Lundbeck (Lundbeck), a subsidiary of The Lundbeck Foundation, carries out the research, development, manufacturing, and marketing of pharmaceuticals for the treatment of central nervous system (CNS) diseases including psychiatric and neurological disorders. The company’s products are indicated for the treatment of Alzheimer’s disease, migraine, depression, Parkinson’s disease, schizophrenia, alcohol dependence, anxiety, bipolar I disorder, depression, anxiety, psychosis, and epilepsy, among others. It operates production facilities in Denmark, Italy, and France, and research centers in the US and Denmark. Lundbeck sells its products primarily to pharmaceutical distributors, pharmacies, and hospitals in Italy, China, Spain, Canada, France, South Korea, Australia, the US, and other countries. Lundbeck is headquartered in Valby, Denmark.
For a complete picture of Lu-AG22515’s drug-specific PTSR and LoA scores, buy the report here.